[1]
|
Spagnolo, P., Distler, O., Ryerson, C.J., Tzouvelekis, A., Lee, J.S., Bonella, F., Bouros, D., Hoffmann-Vold, A.M., Crestani, B. and Matteson, E.L. (2021) Mechanisms of Progressive Fibrosis in Connective Tissue Disease (CTD)-Associated Interstitial Lung Diseases (ILDs). Annals of the Rheumatic Diseases, 80, 143-150.
https://doi.org/10.1136/annrheumdis-2020-217230
|
[2]
|
Cerro Chiang, G. and Parimon, T. (2023) Understanding Interstitial Lung Diseases Associated with Connective Tissue Disease (CTD-ILD): Genetics, Cellular Pathophysiology, and Biologic Drivers. International Journal of Molecular Sciences, 24, Article 2405. https://doi.org/10.3390/ijms24032405
|
[3]
|
Joy, G.M., Arbiv, O.A., Wong, C.K., Lok, S.D., Adderley, N.A., Dobosz, K.M., Johannson, K.A. and Ryerson, C.J. (2023) Prevalence, Imaging Patterns and Risk Factors of Interstitial Lung Disease in Connective Tissue Disease: A Systematic Review and Meta-Analysis. European Respiratory Review, 32, Article ID: 220210.
https://doi.org/10.1183/16000617.0210-2022
|
[4]
|
Jee, A.S. and Corte, T.J. (2019) Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs, 79, 1511-1528. https://doi.org/10.1007/s40265-019-01178-x
|
[5]
|
Jee, A.S., Sheehy, R., Hopkins, P., Corte, T.J., Grainge, C., Troy, L.K., Symons, K., Spencer, L.M., Reynolds, P.N., Chapman, S., de Boer, S., Reddy, T., Holland, A.E., Chambers, D.C., Glaspole, I.N., Jo, H.E., Bleasel, J.F., Wrobel, J.P., Dowman, L., Parker, M.J.S., Wilsher, M.L., Goh, N.S.L., Moodley, Y. and Keir, G.J. (2021) Diagnosis and Management of Connective Tissue Disease-Associated Interstitial Lung Disease in Australia and New Zealand: A Position Statement from the Thoracic Society of Australia and New Zea-land. Respirology, 26, 23-51.
https://doi.org/10.1111/resp.13977
|
[6]
|
Oldham, J.M., Lee, C.T., Wu, Z., Bowman, W.S., Pugashetti, J.V., Dao, N., Tonkin, J., Seede, H., Echt, G., Adegunsoye, A., Chua, F., Maher, T.M., Garcia, C.K., Strek, M.E., Newton, C.A. and Molyneaux, P.L. (2022) Lung Function Trajectory in Progressive Fibrosing Interstitial Lung Disease. European Respiratory Journal, 59, Article ID: 2101396.
https://doi.org/10.1183/13993003.01396-2021
|
[7]
|
Zheng, B., Donohoe, K., Hambly, N., Johannson, K.A., As-sayag, D., Fisher, J.H., Manganas, H., Marcoux, V., Khalil, N., Kolb, M. and Ryerson, C.J. (2022) Clinical Relevance of Rheumatoid Factor and Anti-Citrullinated Peptides in Fibrotic Interstitial Lung Disease. Respirology, 27, 854-862. https://doi.org/10.1111/resp.14301
|
[8]
|
Zheng, J.N., Li, Y., Yan, Y.M., Yu, Y., Shao, W.Q. and Wang, Q. (2020) Increased Serum Calpain Activity Is Associated with HMGB1 Levels in Systemic Sclerosis. Arthritis Research & Ther-apy, 22, Article No. 110.
https://doi.org/10.1186/s13075-020-02195-y
|
[9]
|
Lee, J.S., Lee, E.Y., Ha, Y.J., Kang, E.H., Lee, Y.J. and Song, Y.W. (2019) Serum KL-6 Levels Reflect the Severity of Interstitial Lung Disease Associated with Connective Tissue Disease. Arthritis Research & Therapy, 21, Article No. 58. https://doi.org/10.1186/s13075-019-1835-9
|
[10]
|
Meng, K., Tian, M., Gui, X., Xie, M., Gao, Y., Shi, S., Zhao, T., Xiao, Y., Cai, H. and Ding, J. (2022) Human Epididymis Protein 4 Is Associated with Severity and Poor Prognosis of Connective Tissue Disease-Associated Interstitial Lung Disease with Usual Interstitial Pneumonia Pattern. International Immunopharmacology, 108, Article ID: 108704.
https://doi.org/10.1016/j.intimp.2022.108704
|
[11]
|
Hoffmann, T., Oelzner, P., Franz, M., Teichgräber, U., Renz, D., Förster, M., Böttcher, J., Kroegel, C., Schulze, P.C., Wolf, G. and Pfeil, A. (2022) Assessing the Diagnostic Value of a Potential Screening Tool for Detecting Early Interstitial Lung Disease at the Onset of Inflammatory Rheumatic Diseases. Arthritis Research & Therapy, 24, Article No. 107. https://doi.org/10.1186/s13075-022-02786-x
|
[12]
|
Wang, Y., Xie, X., Zheng, S., Du, G., Chen, S., Zhang, W., Zhuang, J., Lin, J., Hu, S., Zheng, K., Mikish, A., Xu, Z., Zhang, G., Gargani, L., Bruni, C., Hoffmann-Vold, A.M., Matucci-Cerinic, M. and Furst, D.E. (2022) Serum B-Cell Activating Factor and Lung Ultrasound B-Lines in Connective Tissue Disease Related Interstitial Lung Disease. Frontiers in Medi-cine, 9, Article 1066111. https://doi.org/10.3389/fmed.2022.1066111
|
[13]
|
Xie, H.Q., Zhang, W.W., Sun, S., Chen, X.M., Yuan, S.F., Gong, Z.H. and Liu, L. (2019) A Simplified Lung Ultrasound for the Diagnosis of Interstitial Lung Disease in Connective Tissue Disease: A Meta-Analysis. Arthritis Research & Therapy, 21, Article No. 93. https://doi.org/10.1186/s13075-019-1888-9
|
[14]
|
Jiang, X., Su, N., Quan, S., E, L. and Li, R. (2023) Computed Tomography Radiomics-Based Prediction Model for Gender-Age-Physiology Staging of Connective Tissue Dis-ease-Associated Interstitial Lung Disease. Academic Radiology. https://doi.org/10.1016/j.acra.2023.01.038
|
[15]
|
Broens, B., Duitman, J.W., Zwezerijnen, G.J.C., Nossent, E.J., van der Laken, C.J. and Voskuyl, A.E. (2022) Novel Tracers for Molecular Imaging of Interstitial Lung Disease: A State of the Art Review. Autoimmunity Reviews, 21, Article ID: 103202. https://doi.org/10.1016/j.autrev.2022.103202
|
[16]
|
Hata, K., Yanagihara, T., Matsubara, K., Kunimura, K., Suzuki, K., Tsubouchi, K., Eto, D., Ando, H., Uehara, M., Ikegame, S., Baba, Y., Fukui, Y. and Okamoto, I. (2023) Mass Cy-tometry Identifies Characteristic Immune Cell Subsets in Bronchoalveolar Lavage Fluid from Interstitial Lung Diseases. Frontiers in Immunology, 14, Article 1145814.
https://doi.org/10.3389/fimmu.2023.1145814
|
[17]
|
Rzepka-Wrona, P., Skoczyński, S. and Barczyk, A. (2022) Are There Differences in Inflammatory and Fibrotic Pathways between IPAF, CTD-ILDs, and IIPs? A Single-Center Pilot Study. International Journal of Molecular Sciences, 23, Article 15205. https://doi.org/10.3390/ijms232315205
|
[18]
|
Weng, L., Liu, W., Wang, L., Wu, Z., Liu, D., Lin, Y., Song, S., Yu, C., Chen, Y., Chen, J. and Ge, S. (2022) Serum MUC5AC Protein Levels Are Correlated with the Development and Se-verity of Connective Tissue Disease-Associated Pulmonary Interstitial Lesions. Frontiers in Immunology, 13, Article 987723.
https://doi.org/10.3389/fimmu.2022.987723
|
[19]
|
Romero-Bueno, F.I., Rodríguez-Nieto, M.J., Palacios Miras, C., Martínez Estupiñán, L., Martínez-Becerra, M.J., Vegas Sánchez, M.C., Cedeño Díaz, O.M. and Sánchez-Pernaute, O. (2023) Fine-Tuning Characterization of Patients with Interstitial Pneumonia and an Underlying Autoimmune Disease in Real-World Practice: We Get Closer with Nailfold Videocapillaroscopy. Frontiers in Medicine, 10, Article 1057643. https://doi.org/10.3389/fmed.2023.1057643
|
[20]
|
Dsouza, K.G., Surolia, R., Kulkarni, T., Li, F.J., Singh, P., Zeng, H., Stephens, C., Kumar, A., Wang, Z. and Antony, V.B. (2023) Use of a Pulmosphere Model to Evaluate Drug Antifi-brotic Responses in Interstitial Lung Diseases. Respiratory Research, 24, Article No. 96. https://doi.org/10.1186/s12931-023-02404-7
|
[21]
|
Graham, J., Bauer Ventura, I., Newton, C.A., Lee, C., Boctor, N., Pugashetti, J.V., Cutting, C., Joerns, E., Sandhu, H., Chung, J.H., Garcia, C.K., Kadoch, M., Noth, I., Adegunsoye, A., Strek, M.E. and Oldham, J.M. (2020) Myositis-Specific Antibodies Identify A Distinct Interstitial Pneumonia with Au-toimmune Features Phenotype. European Respiratory Journal, 56, Article ID: 2001205. https://doi.org/10.1183/13993003.01205-2020
|
[22]
|
Xu, L., Wang, F. and Luo, F. (2022) Rituximab for the Treat-ment of Connective Tissue Disease-Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 13, Article 1019915.
https://doi.org/10.3389/fphar.2022.1019915
|
[23]
|
Maher, T.M., Tudor, V.A., Saunders, P., Gibbons, M.A., Fletch-er, S.V., Denton, C.P., Hoyles, R.K., Parfrey, H., Renzoni, E.A., Kokosi, M., Wells, A.U., Ashby, D., Szigeti, M. and Molyneaux, P.L. (2023) Rituximab versus Intravenous Cyclophosphamide in Patients with Connective Tissue Dis-ease-Associated Interstitial Lung Disease in the UK (RECITAL): A Double-Blind, Double-Dummy, Randomised, Con-trolled, Phase 2b Trial. The Lancet Respiratory Medicine, 11, 45-54.
|
[24]
|
Liossis, S.C. and Bounia C.A., (2022) Treat-ing Autoimmune-Related Interstitial Lung Disease with B Cell Depletion. Frontiers in Medicine, 9, Article 937561. https://doi.org/10.3389/fmed.2022.937561
|
[25]
|
Wang, J., Wang, X., Qi, X., Sun, Z., Zhang, T., Cui, Y. and Shu, Q. (2022) The Efficacy and Safety of Pirfenidone Combined with Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study. Frontiers in Medicine, 9, Article 871861.
https://doi.org/10.3389/fmed.2022.871861
|
[26]
|
Deng, L., Chen, Y., Hu, X., Zhou, J. and Zhang, Y. (2021) Case Report: Successful Treatment of Refractory Interstitial Lung Disease with Cyclosporine A and Pirfenidone in a Child with SLE. Frontiers in Immunology, 12, Article 708463.
https://doi.org/10.3389/fimmu.2021.708463
|
[27]
|
Yin, X., Zhao, S., Xiang, N., Chen, J., Xu, J. and Zhang, Y. (2023) Efficacy and Safety of Chinese Herbal Medicines Combined with Cyclophosphamide for Connective Tissue Dis-ease-Associated Interstitial Lung Disease: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacolo-gy, 14, Article 1064578.
https://doi.org/10.3389/fphar.2023.1064578
|
[28]
|
Li, Y., Zhu, W., He, H., Garov, Y.A., Bai, L., Zhang, L., Wang, J., Wang, J. and Zhou, X. (2021) Efficacy and Safety of Tripterygium Wilfordii Hook. F for Connective Tissue Dis-ease-Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 12, Ar-ticle 691031.
https://doi.org/10.3389/fphar.2021.691031
|
[29]
|
Zhu, W., Wang, Y., Liu, C., Wu, Y., Li, Y. and Wang, Y. (2022) Connective Tissue Disease-Related Interstitial Lung Disease Is Alleviated by Tripterine through Inhibition of the PI3K/Akt, Apoptosis, and TNF-α Signalling Pathways. Frontiers in Pharmacology, 13, Article 990760. https://doi.org/10.3389/fphar.2022.990760
|
[30]
|
Liu, Y., Hu, M., Fan, G., Xing, N. and Zhang, R. (2022) Effect of Baricitinib on the Epithelial-Mesenchymal Transition of Alveolar Epithelial Cells Induced by IL-6. International Im-munopharmacology, 110, Article ID: 109044.
https://doi.org/10.1016/j.intimp.2022.109044
|
[31]
|
Tomassetti, S., Ravaglia, C., Puglisi, S., Wells, A.U., Ryu, J.H., Bosi, M., Dubini, A., Piciucchi, S., Girelli, F., Parronchi, P., Lavorini, F., Rosi, E., Luzzi, V., Cerinic, M.M. and Poletti, V. (2023) Clinical Implications of Interstitial Pneumonia with Autoimmune Features Diagnostic Criteria in Idiopathic Pulmonary Fibrosis: A Case Control Study. Frontiers in Medicine, 10, Article 1087485. https://doi.org/10.3389/fmed.2023.1087485
|
[32]
|
Natalini, J.G., Diamond, J.M., Porteous, M.K., Lederer, D.J., Wille, K.M., Weinacker, A.B., Orens, J.B., Shah, P.D., Lama, V.N., McDyer, J.F., Snyder, L.D., Hage, C.A., Singer, J.P., Ware, L.B., Cantu, E., Oyster, M., Kalman, L., Christie, J.D., Kawut, S.M. and Bernstein, E.J. (2021) Risk of Pri-mary Graft Dysfunction following Lung Transplantation in Selected Adults with Connective Tissue Disease-Associated Interstitial Lung Disease. The Journal of Heart and Lung Transplantation, 40, 351-358. https://doi.org/10.1016/j.healun.2021.01.1391
|
[33]
|
Zhang, N., Liu, S., Zhang, Z., Liu, Y., Mi, L. and Xu, K. (2023) Lung Transplantation: A Viable Option for Connective Tissue Disease? Arthritis Care & Research. https://doi.org/10.1002/acr.25133
|
[34]
|
Gao, Y., Zhao, Q., Qiu, X., Zhuang, Y., Yu, M., Dai, J., Cai, H. and Yan, X. (2020) Vitamin D Levels Are Prognostic Factors for Connective Tissue Disease Associated Interstitial Lung Disease (CTD-ILD). Aging, 12, 4371-4378.
https://doi.org/10.18632/aging.102890
|
[35]
|
Chiu, Y.H., Koops, M.F.M., Voortman, M., van Es, H.W., Langezaal, L.C.M., Welsing, P.M.J., Jamnitski, A., Wind, A.E., van Laar, J.M., Grutters, J.C. and Spierings, J. (2023) Prognostica-tion of Progressive Pulmonary Fibrosis in Connective Tissue Disease-Associated Interstitial Lung Diseases: A Cohort Study. Frontiers in Medicine, 10, Article 1106560. https://doi.org/10.3389/fmed.2023.1106560
|
[36]
|
Nagy, A., Nagy, T., Kolonics-Farkas, A.M., Eszes, N., Vincze, K., Barczi, E., Tarnoki, A.D., Tarnoki, D.L., Nagy, G., Kiss, E., Maurovich-Horvat, P., Bohacs, A. and Müller, V. (2021) Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline. Frontiers in Pharmacology, 12, Article 778649.
https://doi.org/10.3389/fphar.2021.778649
|